8-K filed April 23, 2025, 7:59 PM ET ticker CLDI CIK 0001855485

leadership confidence high sentiment neutral materiality 0.65

Calidi appoints Eric Poma as CEO; Allan Camaisa resigns, remains director

Calidi Biotherapeutics, Inc.

Allan Camaisa resigned as CEO and Chairman, effective April 21, 2025; will stay as Class III director and CEO Emeritus.
Eric Poma, Ph.D. named CEO and Class I director effective April 22, 2025; previously CEO of Molecular Templates (MTEM).
Poma receives $535k base salary, target bonus up to 50% of base, and option grant for 726,412 shares vesting over 4 years.
Camaisa gets $500k separation over 12 months, COBRA for 12 months, $10k/month transition pay, plus possible incentives through Dec 2026.
James Schoeneck appointed Chairman; board size increased from 5 to 6 members.

item 1.01 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eric Poma

Class I Director

CLDI · Calidi Biotherapeutics, Inc.

Effective: 2025-04-22
Filed: April 23, 2025, 7:59 PM ET

the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Poma to serve as a Class I director of the Company, also effective April 22, 2025

Departed

Allan Camaisa

Chairman of the Board

CLDI · Calidi Biotherapeutics, Inc.

Effective: 2025-04-21
Filed: April 23, 2025, 7:59 PM ET

Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board

Appointed

Eric Poma

Chief Executive Officer

CLDI · Calidi Biotherapeutics, Inc.

Effective: 2025-04-22
Filed: April 23, 2025, 7:59 PM ET

the Board, by a unanimous vote, appointed Eric Poma, Ph.D. to serve as CEO of the Company, effective April 22, 2025.

Departed

Allan Camaisa

Chief Executive Officer

CLDI · Calidi Biotherapeutics, Inc.

Effective: 2025-04-21
Successor: Eric Poma
Filed: April 23, 2025, 7:59 PM ET

Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Eric Poma was appointed as Class I Director at Calidi Biotherapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Poma to serve as a Class I director of the Company, also effective April 22, 2025

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Allan Camaisa resigned as Chairman of the Board at Calidi Biotherapeutics, Inc..

Action: resigned
Role: Chairman of the Board

Exact text from the filing

Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Eric Poma was appointed as Chief Executive Officer at Calidi Biotherapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Board, by a unanimous vote, appointed Eric Poma, Ph.D. to serve as CEO of the Company, effective April 22, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Allan Camaisa resigned as Chief Executive Officer at Calidi Biotherapeutics, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board

View on SEC.gov

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-005777

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.